EL7.AI
StocksMediumUpdated•Originally published 29 July 2026•Updated 29 July 2026•
1 min read

US Mid-Cap Performance Diverges Following Adaptive and ACRES Earnings Reports

Key Facts

1Align Technology reported record Q2 revenue of $1.06 billion, up 4.3% year-over-year.
2Adaptive Biotechnologies increased its full-year revenue outlook driven by growth in its MRD business.
3FormFactor reported record Q2 results due to high demand for semiconductor testing in data centers and AI.

In a shift reflecting divergent performance within the mid-cap sector, recent Q2 results have highlighted a mix of earnings beats and significant misses. Adaptive Biotechnologies reported a quarterly loss of $0.1 per share, performing better than the analyst consensus of a $0.13 loss. Conversely, ACRES Commercial (ACR) faced substantial pressure after reporting a loss of $0.74 per share, missing the expected earnings of $0.11 by a wide margin.

Per market data, these results underscore an operational divide as firms like Align Technology and FormFactor capitalize on data center demand while others face financial headwinds. As of the July 28, 2026 close, Align Technology (ALGN) finished at $175.6 and FormFactor (FORM) at $88.23. The market is now assessing the impact of ACRES' significant earnings miss on broader sentiment within the commercial finance and mid-cap space.

Based on closing prices on July 28, 2026, Adaptive Biotechnologies (ADPT) stands at $22.52 and Corcept Therapeutics (CORT) at $94.19. With no immediate macroeconomic catalysts in the upcoming calendar, traders will focus on whether mid-cap firms can maintain revenue growth while stabilizing earnings per share in a volatile reporting environment.